Patents by Inventor Leonid Beigelman

Leonid Beigelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20180155384
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 7, 2018
    Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Christian Andreas Jekle
  • MODIFIED OLIGONUCLEOTIDES AND METHODS OF USE
    Publication number: 20180135054
    Abstract: Modified oligonucleotides comprising modifications at the 2? and/or 3? positions(s) along with methods of making and use, e.g., against HBV are disclosed.
    Type: Application
    Filed: September 14, 2017
    Publication date: May 17, 2018
    Applicant: Alios Biopharma, Inc.
    Inventors: Sergei GRYAZNOV, Leonid Beigelman, Antitsa Dimitrova Stoycheva, Saul Martinez Montero, Jin Hong
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 9957517
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: May 1, 2018
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9932363
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: April 3, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Natalia Dyatkina, Guangyi Wang, Leonid Beigelman, Vivek Kumar Rajwanshi
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20180079774
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Application
    Filed: October 27, 2017
    Publication date: March 22, 2018
    Inventors: Leonid Beigelman, Jerome Deval, Zhinan Jin
  • ANTIVIRAL COMPOUNDS
    Publication number: 20180065932
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: August 16, 2017
    Publication date: March 8, 2018
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He, Karin Ann Stein
  • Methods of preparing substituted nucleoside analogs
    Patent number: 9908914
    Abstract: Disclosed herein are methods of preparing a nucleoside analog (I) by a reaction that includes an intermediate (GG): Nucleoside analog (I) is useful in treating diseases and/or conditions such as viral infections.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: March 6, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Vladimir Serebryany, Jyanwei Liu, Leonid Beigelman
  • SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF
    Publication number: 20180044369
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Application
    Filed: October 23, 2017
    Publication date: February 15, 2018
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9890188
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: February 13, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Guangyi Wang, David Bernard Smith, Leonid Beigelman, Christian Andreas Jekle
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9862743
    Abstract: Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Picornavirus and/or Flaviviridae infection with one or more nucleosides, nucleotides and nucleotide analogs.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: January 9, 2018
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith, Marija Prhavc, Christian Andreas Jekle, Jerome Deval
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20170342416
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: August 15, 2017
    Publication date: November 30, 2017
    Inventors: James McSwiggen, Leonid Beigelman, Chandra Vargeese
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9815864
    Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same, of the Formula (I). Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a norovirus, with a nucleoside, a nucleotide and an analog thereof.
    Type: Grant
    Filed: June 24, 2014
    Date of Patent: November 14, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, Jerome Deval, Zhinan Jin
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20170298355
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: June 29, 2017
    Publication date: October 19, 2017
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS
    Publication number: 20170283429
    Abstract: Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Inventors: Guangyi Wang, Leonid Beigelman, Anh Truong, Carmela Napolitano, Daniele Andreotti, Haiying He
  • RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
    Publication number: 20170283816
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Application
    Filed: June 8, 2017
    Publication date: October 5, 2017
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 9771588
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: September 26, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: James McSwiggen, Leonid Beigelman, Chandra Vargeese
  • METHOD OF PREPARING AZA-PYRIDONE COMPOUNDS
    Publication number: 20170260189
    Abstract: Disclosed herein are methods for obtaining aza-pyridone compounds, which can be useful for ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection.
    Type: Application
    Filed: March 10, 2017
    Publication date: September 14, 2017
    Inventors: Michael Hunter WELCH, Leonid BEIGELMAN, Robert Than HENDRICKS, Andras HORVATH, Gareth BROWN, Prasad GANJI, Stefan MIX
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 9758544
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: September 12, 2017
    Assignee: Alios BioPharma, Inc.
    Inventors: Leonid Beigelman, David Bernard Smith, Guangyi Wang, Natalia Dyatkina
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 9738899
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: August 22, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese
  • RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
    Patent number: 9732344
    Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: March 30, 2016
    Date of Patent: August 15, 2017
    Assignee: SIRNA THERAPEUTICS, INC.
    Inventors: Leonid Beigelman, James McSwiggen, Chandra Vargeese